Summary
IDEXX Laboratories Inc. reported solid revenue growth of 4.7% to $3.37 billion for the fiscal year ended December 31, 2022. This growth was primarily driven by the Companion Animal Group (CAG), which saw an 8.4% organic revenue increase, demonstrating continued demand for veterinary diagnostics and services. Despite a slight decrease in clinical visits, revenue per practice grew, highlighting increased utilization of diagnostic products. The Water segment also showed positive organic growth of 9.7%. However, the Livestock, Poultry, and Dairy (LPD) segment experienced a decline, largely due to reduced demand in China for swine testing. Research and development expenses saw a significant increase (58.3%) due to strategic investments in technology licensing. The company highlighted its strong gross profit margin of 59.5%, supported by price gains and efficiency initiatives, though facing increased costs in freight, distribution, and labor. IDEXX also actively managed its capital through share repurchases and a $1.25 billion credit facility, ending the year with $112.5 million in cash and cash equivalents. The company remains focused on innovation, customer relationships, and operational efficiency to navigate a competitive landscape and maintain long-term value creation for shareholders.
Financial Highlights
54 data points| Revenue | $3.37B |
| Cost of Revenue | $1.36B |
| Gross Profit | $2.00B |
| R&D Expenses | $254.82M |
| Operating Expenses | $1.11B |
| Operating Income | $898.76M |
| Interest Expense | $39.86M |
| Net Income | $679.09M |
| EPS (Basic) | $8.12 |
| EPS (Diluted) | $8.03 |
| Shares Outstanding (Basic) | 83.62M |
| Shares Outstanding (Diluted) | 84.60M |
Key Highlights
- 1IDEXX Laboratories reported total revenue of $3.37 billion for fiscal year 2022, a 4.7% increase year-over-year.
- 2The Companion Animal Group (CAG) was the primary growth driver, with organic revenue increasing by 8.4%, showcasing continued strong demand in the veterinary diagnostics market.
- 3Gross profit margin remained robust at 59.5%, an improvement from the previous year, driven by price increases and operational efficiencies, although tempered by rising freight, distribution, and labor costs.
- 4Research and Development (R&D) expenses increased significantly by 58.3% to $254.8 million, reflecting strategic investments in technology and innovation.
- 5The company maintained a strong balance sheet, ending the year with $112.5 million in cash and cash equivalents and access to a $1.25 billion credit facility.
- 6The Livestock, Poultry, and Dairy (LPD) segment experienced a revenue decline of 9.8%, primarily attributed to decreased demand for swine testing in China.
- 7IDEXX actively engaged in share repurchases, buying back approximately 2.0 million shares during the fiscal year 2022.